Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?

Abstract

The history of botulinum toxin is fascinating. First recognized as the cause of botulism nearly 200 years ago, it was originally feared as a deadly poison. Over the last 30 years, however, botulinum toxin has been transformed into a readily available medication used to treat a variety of medical disorders. Interest in the use of botulinum toxin has been particularly strong for patients with spastic smooth muscle disorders of the gastrointestinal tract. Patients with achalasia, diffuse esophageal spasm, gastroparesis, sphincter of Oddi dysfunction, and anal fissures have all been treated with botulinum toxin injections, often with impressive results. However, not all patients respond to botulinum toxin therapy, and large randomized controlled trials are lacking for many conditions commonly treated with botulinum toxin. This paper reviews the history, microbiology, and pharmacology of botulinum toxin, discusses its mechanism of action, and then presents recent evidence from the literature regarding the use of botulinum toxin for the treatment of a variety of gastrointestinal tract disorders.

Keywords: Achalasia; anal fissure; botulinum toxin; esophagus; gastroparesis; obesity; sphincter of Oddi.

Figure 1

Structure of botulinum toxin A.

Figure 2

Mechanism of action of botulinum toxin A. Modified from Arnon SS, et al. BTX

botulinum toxin

SNARE

soluble N-ethylmaleivinide-sensitive fusion attachment protein receptor.